Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Oslo University Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare different dosages and ways of administration of indocyanine green during fluorescent cholangiography in laparoscopic cholecystectomy. The study is randomized.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Direct gallbladder injection | Other | 2.5 mg of ICG will be injected directly into gallbladder intraoperatively. |
|
| 2.5 mg intravenously | Other | 2.5 mg will ICG will be injected intravenously 1 hour prior to surgery. |
|
| 2.5 mg intravenously + direct gallbladder injection | Other | 2.5 mg ICG will be injected intravenously 1 hour prior to surgery and another 2.5 mg ICG will be injected directly into the gallbladder intraoperatively. |
|
| 5 mg intravenously | Other | 5 mg ICG will be injected intravenously 0-8 hours prior to surgery. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Direct gallbladder injection of ICG intraoperatively | Procedure | Patients randomized to this arm will have 2.5 mg ICG injected directly into the gallbladder intraoperatively. |
|
| Measure | Description | Time Frame |
|---|---|---|
| A questionnaire will be used to evaluate the surgeons experience. | This study aims to compare the surgeons subjective experience of ICG utility for different dosages and route of administration of indocyanine green in patients operated with laparoscopic cholecystectomy. A questionnaire will be used to evaluate the surgeons experience. | 3-4 months |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Carl-Philip Rancinger, MD | Contact | +4769860000 | carl-philip.rancinger@so-hf.no |
| Name | Affiliation | Role |
|---|---|---|
| Tom Nordby, MD, PhD | Ostfold Hospital Trust, Norway | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Østfold Hospital trust | Recruiting | Moss | Norway |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Intravenous injection 2.5 mg | Procedure | Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prio to surgery |
|
| Intravenous injection and direct gallbladder injection | Procedure | Patients randomized to this arm will have 2.5 mg ICG injected intravenously 1 hour prior to surgery and another 2.5 mg ICG injected directly into the gallbladder, intraoperatively. |
|
| Intravenous injection 5 mg | Procedure | Patients randomized to this arm will have 5 mg ICG injected intravenously 0-8 hours prior to surgery |
|
| ID | Term |
|---|---|
| D042882 | Gallstones |
| D002764 | Cholecystitis |
| ID | Term |
|---|---|
| D002769 | Cholelithiasis |
| D001660 | Biliary Tract Diseases |
| D004066 | Digestive System Diseases |
| D041761 | Cholecystolithiasis |
| D005705 | Gallbladder Diseases |
| D002137 | Calculi |
| D020763 | Pathological Conditions, Anatomical |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| D007275 | Injections, Intravenous |
| ID | Term |
|---|---|
| D061605 | Administration, Intravenous |
| D004333 | Drug Administration Routes |
| D004358 | Drug Therapy |
| D013812 | Therapeutics |
| D007267 | Injections |
Not provided
Not provided